Australia Federal Court Dismisses Cancer Patients' Challenge to Myriad's Gene Patent | GenomeWeb

NEW YORK (GenomeWeb News) – The Federal Court of Australia has dismissed a case in which a group of cancer patients were challenging the viability of a patent held by Myriad Genetics covering mutations in the BRCA1 gene linked to increased risk of hereditary breast and ovarian cancer.

Under Australian patent law, human beings and the biological processes involved in the creation of human beings are not patentable, but any "manner of manufacture," claims that are novel, inventive and useful, are patentable.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.